Enlitic Inc. (ASX: ENL), along with its subsidiary Laitek Inc., has signed a binding memorandum of understanding (MOU) with GE Precision Healthcare LLC. Under the MOU, Laitek will provide between US$3–6 million (AU$ 5–10 million) annually in migration capacity for the next five years. The agreement strengthens Enlitic’s role as a foundational collaborator for GE HealthCare’s Genesis Cloud Product Suite.
The MOU is conditional on Enlitic securing AU$ 10 million in external funding, which has been achieved through firm commitments from new and existing institutional and sophisticated investors via a two-tranche placement. Once GE HealthCare confirms the funding milestone, it will prepay US$2 million for migration services. The funding will accelerate the development of Enlitic’s AI-enabled solutions and data intelligence tools as it works to modernize imaging infrastructure across healthcare systems globally.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jun 25, 2025
Jun 25, 2025
Jun 25, 2025
Jun 25, 2025
Jun 25, 2025
Jun 25, 2025
Jun 25, 2025
Jun 25, 2025
Jun 25, 2025
Jun 25, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
